Celltrion, Inc.
068270
株式のランク
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
株価
$146.63
時価総額
$33.44B
変化（1日）
-1.52%
変化（1年）
23.60%
国
KR
取引 Celltrion, Inc. (068270)
カテゴリー
Healthcare
Celltrion, Inc.（068270）の発行済株式数
June 2026 時点の発行済株式数 233.25M
Celltrion, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 233.25M です。December 2024 の終わりには、同社は 217.00M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Celltrion, Inc.（068270）の発行済株式数の履歴（2007 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 233.25M | 0.99% |
| 2025 | 230.96M | 6.43% |
| 2024 | 217.00M | 52.04% |
| 2023 | 142.73M | 3.35% |
| 2022 | 138.10M | -4.67% |
| 2021 | 144.87M | 0.15% |
| 2020 | 144.65M | 0.14% |
| 2019 | 144.44M | -0.05% |
| 2018 | 144.52M | 0.11% |
| 2017 | 144.35M | 0.26% |
| 2016 | 143.98M | 2.91% |
| 2015 | 139.90M | 2.76% |
| 2014 | 136.14M | -0.01% |
| 2013 | 136.16M | -0.96% |
| 2012 | 137.49M | -0.65% |
| 2011 | 138.39M | 4.84% |
| 2010 | 132.00M | 8.34% |
| 2009 | 121.83M | 3.78% |
| 2008 | 117.40M | 1,578.29% |
| 2007 | 7.00M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 8.86% |
US
|
|
| 396.00M | 69.78% |
US
|
|
| 478.91M | 105.33% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -73.34% |
NL
|
